Elevated expression of Pglyrp 1 in peripheral blood mononuclear cells and PGLYRP-1 in serum from systemic lupus erythematosus patients

Qing Luo,Fangyi Yao,Lu Zhang,Xue Li,Cheng Qing,Rigu Su,Yang Guo,Zikun Huang,Junming Li
2019-01-01
Abstract:Background: Peptidoglycan recognition protein-1 (PGLYRP-1) is part of the innate immune system. It has been established that disorders of innate immune response are found in systemic lupus erythematosus (SLE) patients. However, the roles of pglyrp1/PGLYPR-1 in SLE are poorly understood. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure levels of PGLYPR-1 in serum. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect levels of Pglyrp1 in peripheral blood mononuclear cells (PBMCs) and correlation analysis was used to analyze the relationship between levels of Pglyrp1 in PBMCs and clinical characteristics. A receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic value of Pglyrp1 in PBMCs. Results: Expression of Pglyrp1 in PBMCs and PGLYPR-1 in serum from SLE patients was significantly increased, compared to healthy controls (HC). ROC curve analysis suggested that Pglyrp1 in PBMCs had significant value of SLE diagnosis (AUC = 0.776), followed by PGLYPR-1 in serum (AUC = 0.695). Pglyrp1 in PBMCs provided better diagnostic accuracy. Risk scores, based on Pglyrp1 in PBMCs, also significantly distinguished SLE patients from rheumatoid arthritis (RA) patients. Levels of Pglyrp1 in PBMCs were positively associated with erythrocyte sedimentation rates (ESR), C-reactive protein (CRP), and neutrophils (%). Levels of Pglyrp1 in PBMCs were negatively correlated with red blood cells (RBC), hematocrit (HCT), and lymphocytes. Conclusion: Pglyrp1 and PGLYPR-1 protein dysregulation may play a role in SLE pathogenesis. Increased expression of Pglyrp1 in PBMCs from SLE patients may serve as a potential biomarker for SLE patients in the future.
What problem does this paper attempt to address?